# Empagliflozin Treatment in Kidney Transplant Recipients

Study · id `cardio:ct-nct06013865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06013865](<https://clinicaltrials.gov/study/NCT06013865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06013865

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.

## Technical summary

Registry record NCT06013865. Allocation not applicable; no masking; primary purpose treatment. Start 2024-04-05 (actual); primary completion 2030-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT06013865, source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)
- Started: 2024-04-05 (actual) (ClinicalTrials.gov record NCT06013865, source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)
- Primary completion: 2030-03-31 (anticipated) (ClinicalTrials.gov record NCT06013865, source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)
- Completion: 2030-03-31 (anticipated) (ClinicalTrials.gov record NCT06013865, source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06013865, source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06013865-2026-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin Treatment in Kidney Transplant Recipients
- Acronym: SEKTR
- Condition: Kidney Transplant
- Condition: Chronic Kidney Disease
- Intervention (Drug): Empagliflozin
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED
- Collaborator: Iowa City VA Health Care System
- Collaborator class: FED
- Collaborator: VA Pittsburgh Healthcare System
- Collaborator class: FED
- Collaborator: VA Tennessee Valley Health Care System
- Collaborator class: FED
- Collaborator: VA Hines Health Care
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: ab26ae8ac52d4933ab143d9723804ce6c307f6e4ab10dac42f56c55e83eced7d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
